This Phase II/III trial is trying to determine whether a genetic test called “circulating tumour DNA” is an effective way to decide the specific type and duration of chemotherapy patients with localised pancreatic cancer should receive post-surgery .
This trial is treating patients with pancreatic cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study
Other Non-Commercial Sponsor
Walter and Eliza Hall Institute
All participants in this study will have blood drawn during week 4 and week 8 post-surgery for circulating tumour DNA analysis. They will then be randomly allocated to one of two treatment groups, where the choice of chemotherapy regimen will be made prior to randomisation. Patients are eligible to join this trial if they are at least 18 years old, have undergone curative surgery for localised pancreatic cancer and have been recommended adjuvant chemotherapy
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More